Unknown NA INTERVENTIONAL 2-arm NCT02392520

Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)

GnRH Antagonist in the Luteal Phase Compared to Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) in Whom All Embryos Are Cryopreserved

Sponsor: Eugonia

Conditions Ovarian Hyperstimulation Syndrome

Interventions Placebo cetrorelix (cetrotide)

Updated 7 times since 2017 Last updated: Mar 18, 2015 Started: May 31, 2015 Primary completion: Mar 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02392520, this NA trial focuses on Ovarian Hyperstimulation Syndrome and remains ongoing. Sponsored by Eugonia, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
May 2017 — Jun 2018 [monthly]

Unknown Status NA

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Feb 2017 — May 2017 [monthly]

Not Yet Recruiting NA
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting NA

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eugonia

Data source: Eugonia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Athens, Greece